Feed AVXL
AV

Anavex Life Sciences Corp. AVXL · NASDAQ

$1.48 -1.99% (-$0.03)

Summary

50 / 100 · Bulios Score

What speaks for it

  • It has no debt and holds $127.4M in cash.
  • It beat profit estimates 7 times in the last 8 quarters.

What to watch

  • The share price is above the Bulios Fair Price.
  • It passes only 1 of the 9 points of the Piotroski financial health test.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive

Price against the Bulios Fair Price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

There is not enough revenue history yet to say how fast it grows.

Growth in detail

Does it make money?

Over the last 12 months it made a loss of $13.0M.

Profitability in detail

Is it financially healthy?

Yes

It has no debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $11 is 643% above today's price. 85% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.